Účetní hodnota akcie společnosti ProMIS Neurosciences
Jaká je hodnota metriky Účetní hodnota akcie společnosti ProMIS Neurosciences?
Hodnota metriky Účetní hodnota akcie společnosti ProMIS Neurosciences, Inc. je 0.53
Jaká je definice metriky Účetní hodnota akcie?
Účetní hodnota akcie (Book/Share) se rovná majetku společnosti minus závazky společnosti dělené počtem vydaných akcií.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Účetní hodnota akcie společností v sektoru Health Care sektor na TSX ve srovnání se společností ProMIS Neurosciences
Čemu se věnuje společnost ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Firmy s metrikou účetní hodnota akcie podobnou společnosti ProMIS Neurosciences
- Hodnota metriky Účetní hodnota akcie společnosti Justin Allen je 0.52
- Hodnota metriky Účetní hodnota akcie společnosti Biofrontera AG je 0.52
- Hodnota metriky Účetní hodnota akcie společnosti Shrenik je 0.52
- Hodnota metriky Účetní hodnota akcie společnosti Ngm Biopharmaceuticals Inc je 0.52
- Hodnota metriky Účetní hodnota akcie společnosti ScoZinc Mining je 0.52
- Hodnota metriky Účetní hodnota akcie společnosti EFT Solutions je 0.52
- Hodnota metriky Účetní hodnota akcie společnosti ProMIS Neurosciences je 0.53
- Hodnota metriky Účetní hodnota akcie společnosti DATATRAK International je 0.53
- Hodnota metriky Účetní hodnota akcie společnosti China MeiDong Auto je 0.53
- Hodnota metriky Účetní hodnota akcie společnosti Alibaba Health Information Technology je 0.53
- Hodnota metriky Účetní hodnota akcie společnosti Bamboos Health Care je 0.53
- Hodnota metriky Účetní hodnota akcie společnosti Interbit je 0.53
- Hodnota metriky Účetní hodnota akcie společnosti Air France-KLM SA je 0.53